News

T-E Pharma has officially launched its pre-initial public offering (pre-IPO) fundraising program. The proceeds will be used to accelerate the development of its novel therapeutic pipeline, expand its global strategic presence, and strengthen its capital structure. The company is also actively pursuing international partnership opportunities, with the goal of listing on the Taiwan Emerging Stock […]

T-E Pharma held its annual year-end gala on January 29, providing an overview of the Group’s R&D achievements and future strategic roadmap. Its subsidiaries, Immunwork and T-E Meds, currently have five drug candidates at critical stages of development. Among them, two candidates are expected to advance into Phase II or Phase IIb clinical trials, with

T-E Pharma announced that its subsidiary, T-E Meds, Inc., has been shortlisted for the prestigious “Best New Drug Developer” category at the 12th World ADC Awards 2025. Selected from a highly competitive pool of global nominees, T-E Meds is one of six finalists to receive this distinguished honor. Since its launch in 2014, the World

On June 24, 2025, T-E Meds and Asymchem Laboratories successfully signed a strategic cooperation agreement. This partnership marks the beginning of a deep strategic collaboration in the field of innovative drug development, with the goal of jointly advancing the global pharmaceutical industry.Ms. Yang Rui, Co-CEO of Asymchem, and Dr. Hsin-Mao Chu, CEO of T-E Meds,

Dr. Tse-Wen Chang, founder and chairman of Immunwork and T-E Meds, shared the latest developments of both companies on 15th January.  Immunwork has developed two ultra-long-acting drugs: TE-8105 and TE-8214. TE-8105 primarily targets type 2 diabetes, obesity, and fatty liver disease, and is scheduled to complete Phase 2a clinical trials this year. TE-8214 focuses on

We are thrilled to announce that T-E Meds has licensed its novel Antibody-Drug Conjugate, TE-1146, to Orient EuroPharma. According to the contract, T-E Meds will receive a signing and licensing fee of NT$270 million (approximately USD 8.5 million) for granting the commercialization rights of the TE-1146 drug in Taiwan, Southeast Asia, New Zealand and the

Immunwork with its “Application of an Innovative Fatty Acid Bundle Platform in the Development of Ultra-Long-Acting Drugs” project, has been honored with the 21st National Innovation Award – Enterprise Innovation Award. This prestigious recognition highlights the excellence of Immunwork’s platform technology and the promising potential drug candidates, earning high acclaim from both national and professional

The founder of Immunwork and T-E Meds, Dr. Tse-Wen Chang, shared the latest developments of the two companies on 11th January. He further announced Immunwork’s planned entry into the clinical stage in 2024. The two long-acting drugs, TE-8105 and TE-8214, are designed to target type-II diabetes, obesity, fatty liver diseases, and neuroendocrine tumors (NETs) as

Website link: https://news.gbimonthly.com/tw/article/show.php?num=61824&range=news